PetMed Express Gestione

Gestione criteri di controllo 1/4

PetMed Express' Il CEO è Sandra Campos, nominato in Apr2024, ha un mandato di meno di un anno. possiede direttamente 0.008% delle azioni della società, per un valore di € 4.57K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.3 anni e 1.8 anni.

Informazioni chiave

Sandra Campos

Amministratore delegato

US$128.2k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.008%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	2yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Sandra Campos (57 yo)

less than a year

Mandato

US$128,183

Compensazione

Ms. Sandra Y. Campos is Independent Director of PetMed Express, Inc. from May 17, 2023 and serves as its CEO and President since April 29, 2024. She serves as an Independent Director at Commerce Fabric, In...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Sandra Campos	President	less than a year	US$128.18k	0.0079% € 5.8k
Christine Chambers	Treasurer & Secretary	2yrs	US$401.34k	0.082% € 60.5k
Robyn DElia	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Caroline Conegliano	Chief Operating Officer	less than a year	Nessun dato	Nessun dato
Doug Krulik	Chief Accounting Officer	less than a year	Nessun dato	Nessun dato
Mark Moseley	Chief Technology & Information Officer	2.8yrs	Nessun dato	0.20% € 150.2k
Carla Dodds	Chief Marketing Officer	less than a year	Nessun dato	Nessun dato
Jacqueline Smith	Vice President of People	2.8yrs	Nessun dato	0.066% € 48.8k
Umesh Sripad	Chief Digital & Technology Officer	less than a year	Nessun dato	Nessun dato
Wendy Zalai	Corporate Controller & Corporate Secretary	3.7yrs	Nessun dato	Nessun dato

0.5yrs

Durata media

Gestione esperta: Il team dirigenziale di PQM non è considerato esperto (durata media 0.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Sandra Campos	President	1.4yrs	US$128.18k	0.0079% € 5.8k
Gian Fulgoni	Independent Director	21.9yrs	US$150.98k	0.55% € 400.7k
Diana Purcel	Independent Director	2.5yrs	US$139.53k	0.058% € 42.5k
Leah Solivan	Independent Director	less than a year	Nessun dato	Nessun dato
Leslie C. Campbell	Independent Chairman of the Board	6.3yrs	US$143.07k	0.21% € 152.0k
Justin Mennen	Independent Director	less than a year	Nessun dato	Nessun dato

2.0yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di PQM non è considerato esperto (durata media del mandato 1.8 anni), il che suggerisce un nuovo consiglio.

PetMed Express Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

PetMed Express, Inc. Appoints Robyn DElia as Chief Financial Officer, Effective September 16, 2024

Petmed Express, Inc. Appoints Doug Krulik as Chief Accounting Officer, Effective August 19, 2024

PetMed Express, Inc., Annual General Meeting, Aug 08, 2024

PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors

PetMed Express, Inc. Announces Christine Chambers Will Leave the Company in Early August 2024

PetMed Express, Inc. Appoints Carla Dodds as Chief Marketing Officer

Recent updates

PetMed Express, Inc. to Report Q2, 2025 Results on Nov 06, 2024

Now 21% overvalued

PetMed Express, Inc. Appoints Robyn DElia as Chief Financial Officer, Effective September 16, 2024

New major risk - Revenue and earnings growth

First quarter 2025 earnings released: EPS: US$0.18 (vs US$0.056 loss in 1Q 2024)

Now 28% overvalued

Petmed Express, Inc. Appoints Doug Krulik as Chief Accounting Officer, Effective August 19, 2024

PetMed Express, Inc. to Report Q1, 2025 Results on Aug 06, 2024

PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 3000 Index

PetMed Express, Inc., Annual General Meeting, Aug 08, 2024

PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors

Full year 2024 earnings released: US$0.37 loss per share (vs US$0.25 profit in FY 2023)

New major risk - Revenue and earnings growth

PetMed Express, Inc. Announces Christine Chambers Will Leave the Company in Early August 2024

PetMed Express, Inc. Appoints Carla Dodds as Chief Marketing Officer

PetMed Express, Inc. to Report Q4, 2024 Results on Jun 11, 2024

PetMed Express, Inc. Appoints Justin Mennen to Board of Directors, Effective June 3, 2024

PetMed Express, Inc. Announces Executive Changes

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. to Report Q3, 2024 Results on Feb 08, 2024

PetMed Express, Inc. Announces Management Changes

Independent Chairman of the Board recently bought €281k worth of stock

CEO, President & Director recently bought €94k worth of stock

Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.13 profit in 2Q 2023)

PetMed Express, Inc. Makes Decision to Suspend the Quarterly Dividend Effective the Quarter Ended September 30, 2023

PetMed Express, Inc. to Report Q2, 2024 Results on Oct 30, 2023

Now 21% undervalued after recent price drop

First quarter 2024 earnings released: US$0.044 loss per share (vs US$0.14 profit in 1Q 2023)

PetMed Express, Inc. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

High number of new directors

Full year 2023 earnings released: EPS: US$0.011 (vs US$1.05 in FY 2022)

PetMed Express, Inc. Declares a Quarterly Dividend, Payable on June 12, 2023

PetMed Express, Inc., Annual General Meeting, Aug 03, 2023

PetMed Express, Inc. Appoints Sandra Y. Campos to its Board of Directors

PetMed Express, Inc. to Report Q4, 2023 Results on May 22, 2023

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.21 profit in 3Q 2022)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on February 27, 2023

Investor sentiment improves as stock rises 17%

PetMed Express, Inc. to Report Q3, 2023 Results on Feb 06, 2023

PetMed Express, Inc. entered into an agreement to acquire PetCareRx, Inc. from Evolution VC Partners and Feenix Venture Partners.

PetMed Express, Inc. entered into an agreement to acquire PetCareRx, Inc. from Evolution VC Partners and Feenix Venture Partners.

Second quarter 2023 earnings released: EPS: US$0.13 (vs US$0.32 in 2Q 2022)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on November 30, 2022

PetMed Express, Inc. to Report Q2, 2023 Results on Nov 07, 2022

Now 20% undervalued

Upcoming dividend of US$0.30 per share

First quarter 2023 earnings released: EPS: US$0.14 (vs US$0.22 in 1Q 2022)

Petmed Express, Inc. Declares Quarterly Dividend, Payable on August 19, 2022

PetMed Express, Inc. Announces Executive Changes

PetMed Express, Inc. to Report Q1, 2023 Results on Jul 25, 2022

PetMed Express, Inc., Annual General Meeting, Jul 28, 2022

PetMed Express, Inc., Annual General Meeting, Jul 28, 2022

Full year 2022 earnings released: EPS: US$1.05 (vs US$1.53 in FY 2021)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on May 27, 2022

PetMed Express, Inc. to Report Q4, 2022 Results on May 09, 2022

PetMed Express, Inc. Appoints Diana Garvis Purcel to Board of Directors, Effective April 4, 2022

Upcoming dividend of US$0.30 per share

PetMed Express, Inc. Provides Sales Guidance for the Year 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2022 earnings released: EPS US$0.32 (vs US$0.42 in 2Q 2021)

Independent Director Frank Formica has left the company

First quarter 2022 earnings released: EPS US$0.22 (vs US$0.39 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$1.53 (vs US$1.29 in FY 2020)

Full year 2021 earnings released: EPS US$1.53 (vs US$1.29 in FY 2020)